Detection of p53 Mutant and isochromosome 17q in Myelodysplastic Syndromes and Leukemias / 대한임상병리학회지

BACKGROUND: The p53 gene is a tumor suppressor gene situated in the short arm of chromosome 17(in 17p13 band). The p53 mutation is often correlated with the worsening or relapsing of the hematologic malignancies, and the loss of the short arm of chromosme 17 is associated with a p53 mutation on the remaining allele in several hematologic malignancies. In this study, we investigated correlations between cytogenetic rearrangements leading to 17p deletion, the presence of mutant p53 protein and single strand conformational polymorphism analysis of the p53 gene in myelodysplastic syndromes and leukemias. METHODS: In this study, we analyzed 60 patients with different hematologic malignancies, including 26 acute myelogenous leukemia, 16 acute lymphoblastic leukemia, 7 myelodysplastic syndrome, and 11 chronic myelogenous leukemia. Cytogenetic analysis of the bone marrow was performed by using the G-banding method. Mutant p53 protein was detected using a mouse monoclonal antibody, which reacts with mutant p53. The Polymerase chain reaction and the single strand conformational polymorphism analysis(PCR-SSCP) of exons 5 to 8 of the p53 gene were performed on only 20 patients with acute myelogenous leukemia. RESULTS: Only 1(1.7%) out of 61 patients showed a deletion of the short arm of chromosome 17 through isochromosome 17q and mutant p53 protein. This patient with chronic myelogenous leukemia underwent a clinical transition from chronic to blastic phase. But, PCR-SSCP of the p53 gene was not performed on this patient with isochromosome 17q and mutant p53 protein. CONCLUSIONS: Even though analysis of the p53 gene by PCR-SSCP was not fully performed, this report suggests that the frequency of p53 mutant may be rare in Korean patients with myelodysplastic syndromes and leukemias. In addition, further investigation is required for the correlation between immunofluorescence and PCR-SSCP to detect p53 mutations.

Percutaneous Ethanol Ablation of Hepatic and Renal Cyst: Therapeutic Effect and Follow-Up Study

PURPOSE: To evaluate the ability of percutaneous ethanol ablation in the treatment of benign cysts of the liver and kidney, and to decide the need and the time of retreatment when the cysts remain on the follow-up ultrasonogram. MATERIALS AND METHODS: Twenty benign cysts(8 hepatic and 12 renal cysts) in 18 patients diagnosed or confirmed either by ultrasound, CT or cytology were treated with percutaneous ethanol injection(PEI). After evacuation of cystic fluid, 15-900ml(amount corresponding to 40-50% of the volume of aspirated fluid) of absolute ethanol(99.9%) was injected into the cysts through the aspiration catheter. rln large cysts, two or more PEIs were done in one session. Follow-up ultrasonographic studies during the period of 12 months with 1-2 months interval after PEI were performed for evaluation of the therapeutic effect. RESULTS: Nine cysts(45%) disappeared completely within 2 months after initial PEI. Although 11 cysts(55.5%) recurred 2 months after initial PEI, 8 of them disappeared within 6 months and one within 8 months after inital PEI without additional PEI. As a result, 18 of 20 cysts(90%) disappeared within 8 months after initial PEI and most of the recurrent cysts disappeared within 6 months without additional PEI. No major complications were encountered concerning PEI, although transient abdominal pain, elevation of body temperature, and drowsiness were noted in 8 patients. CONCLUSION: PEI is an effective and safe modality for the treatment of benign hepatic or renal cysts and the apparent recurrence within 6 months after initial PEI might be mostly a transient, reactive or inflammatory fluid collection rather than real recurrence.

Right ventricular ejection fraction using ECG-Gated first pass cardioangiography / 대한핵의학회잡지

No abstract available.

Radiologic evaluation of adriamycin induced toxic cardiomyopathy in childhood leukemia

The cardiomyopathy associated with Adriamycin is frequently fatal and full clinical recovery is uncommon. To evaluate the radiological manifestation and the outcome of Adriamycin induced cardiac toxicity, we retrospectively reviewed the serial chest X-ray films of children treated with Adriamycin. Among 154 children with leukemia, fourteen patients developed clinical and radiologic evidence of congestive heart failure(CHF), Six out of 14(43%) died of CHF within 2 weeks after attack and eight children survived after their acute episodes of CHF, were controlled following digoxin and diuretic therapy. Despite the improving clinical evidence of heart failure, the follow-up chest roentgenograms of these 8 children showed definite cardiomegaly as compared with the pre-treatment chest X-ray. Three children among 8 had minimal cardiomegaly and the remaining five children showed persistent, marked cardiomegaly during the period of 9-25 months of follow up. In summary, when CHF develops during chemotherapy in leukemic children, the possibility of Adriamycin induced cardiac toxicity should be suspected. Our findings showed that persistence of cardiomegaly represented significant cardiomyopathy despite clinical improvement of CHF.